HighTower Advisors
DMK

HighTower Advisors’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

HighTower Advisors’s Portfolio DMK Stock Details DMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,114
Closed -$14K – 3463
2022
Q2 		$14K Buy
1,114
+1,103
+10,027% +$34.4K ﹤0.01% 3042
2022
Q1 		$11K Buy
+11
New +$472 ﹤0.01% 3214
2021
Q3 		– Sell
-371
Closed -$12K – 3493
2021
Q2 		$12K Buy
+371
New +$22.6K ﹤0.01% 2992

Other funds holding DMK

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

HighTower Advisors's DMK Position: Q1 2023 in Review

HighTower Advisors sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q1 2023, closing a stake of 819 shares — an estimated $9K sold.

HighTower Advisors first reported a position in DMK in Q2 2014 and held it in 20 quarters. The position peaked at $317K in Q2 2014. 47 funds tracked by Wall St. Rank hold DMK as of Q1 2023.

  • HighTower Advisors reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q1 2023 after selling out during the quarter.
  • HighTower Advisors sold 819 DMK Pharmaceuticals Corporation Common Stock shares in Q1 2023, an estimated $9K.
  • HighTower Advisors first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q2 2014 and held it in 20 quarters.
  • HighTower Advisors's DMK Pharmaceuticals Corporation Common Stock position peaked at $317K in Q2 2014.
  • 47 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q1 2023.

Based on HighTower Advisors's 13F filing for Q1 2023, filed 12 May 2023.